Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Hespecta in Patients Treated for HPV16-positive Tumors or Premalignant Lesions
NCT02821494Phase 1Completed
- Sponsor
- Leiden University
- Start
- Mar 2015
- Primary completion
- Mar 2020
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of synthetic human papillomavirus 16 E6 peptide in human papillomavirus type 16 infection, Human papillomavirus-associated neoplasm and Precancerous lesion, sponsored by Leiden University. Primary endpoint: Biological activity of Hespecta at 26 weeks. Started Mar 2015; status: completed.
02
Drugs
synthetic human papillomavirus 16 E6 peptide
03
Conditions
human papillomavirus type 16 infectionHuman papillomavirus-associated neoplasmPrecancerous lesion
Beyond the preview
Go deeper on NCT02821494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02821494.